Cite
HARVARD Citation
Clavio, M. et al. (2021). Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Cancer. 127 (12), pp. 2015-2024. [Online].